Emcure Pharmaceuticals vs Merck India: Share Price, Comparison and Key Differences

Emcure Pharmaceuticals MCap Rs 37,502 Cr, PE 36.80x, ROE 18.67%. Merck India MCap Rs 10,208 Cr, PE 31.22x, ROE 62.32%, Div 6.75%.

Updated: 11 Aug 2026 • 1:05 pm

Posted by:

Emcure Pharmaceuticals vs Merck India: Share Price, Comparison and Key Differences

Emcure Pharmaceuticals vs Merck India is a comparison branded pharma investors look up when evaluating two listed Indian pharmaceutical companies selling branded medicines in the Indian market. Emcure Pharmaceuticals, a Pune-based company promoted by the Doshi family, is a branded generics pharmaceutical company selling products in women's health, oncology, HIV/ARV and cardiology in India and internationally. Merck India (listed as Merck Ltd), a subsidiary of Merck KGaA (Germany), sells branded healthcare products including Neurobion (Vitamin B complex), Becosules, Glucophage (Metformin for diabetes), Polybion and Cetaphil skincare in India.

This Emcure Pharmaceuticals vs Merck India article covers reach and market position, key products, latest declared results and stock valuation. The Emcure Pharmaceuticals vs Merck India data below is sourced from Groww and public company filings and reflects the most recently available information at the time of writing.

Table of Contents

Emcure Pharmaceuticals vs Merck India: Reach and Market Position

On the Emcure Pharmaceuticals side of the Emcure Pharmaceuticals vs Merck India comparison, Emcure Pharmaceuticals sells branded generics in gynecology, oncology, HIV/ARV, cardiology and vitamins/minerals across India and exports. Market capitalisation is Rs 37,502 Cr.

Click Here – Get Free Investment Predictions

On the Merck India side of the Emcure Pharmaceuticals vs Merck India comparison, Merck India sells specialty branded healthcare products (Neurobion, Becosules, Glucophage, Polybion, Cetaphil) through the Indian retail and prescription channels. Market capitalisation is Rs 10,208 Cr.

Emcure Pharmaceuticals vs Merck India: Key Products and Business Mix

In the Emcure Pharmaceuticals vs Merck India product comparison, Emcure Pharmaceuticals offers: Emcure earns from branded generic drugs across women's health, oncology, ARV and cardiovascular. EPS is Rs 53.72. PE is 36.80x, ROE 18.67 percent, D/E 0.31.

For Merck India in this Emcure Pharmaceuticals vs Merck India breakdown: Merck India earns from branded health products (Neurobion, Becosules B vitamins, Glucophage diabetes), skincare (Cetaphil) and specialty pharma. EPS is Rs 196.94. PE is 31.22x, ROE 62.32 percent, D/E 0.02. Dividend yield is 6.75 percent.

Emcure Pharmaceuticals vs Merck India: Latest Results

The Emcure Pharmaceuticals vs Merck India results for Emcure Pharmaceuticals: Emcure has a market cap of Rs 37,502 Cr and PE of 36.80x. ROE is 18.67 percent. Emcure listed in 2024 and is 3.7 times larger than Merck India.

The Emcure Pharmaceuticals vs Merck India results for Merck India: Merck India has a market cap of Rs 10,208 Cr and PE of 31.22x. ROE is an extraordinary 62.32 percent – reflecting its asset-light, high-margin branded healthcare business with minimal capital requirements. Dividend yield is 6.75 percent.

Compare Emcure Pharmaceuticals and Merck India Fundamentals on the Univest Screener

Emcure Pharmaceuticals vs Merck India: Stock and Valuation

The Emcure Pharmaceuticals vs Merck India stock comparison uses the latest available market data from Groww. Investors tracking Emcure Pharmaceuticals vs Merck India should verify current prices on NSE or BSE before trading.

Emcure vs Merck India at current valuations: Emcure trades at Rs 37,502 Cr market cap, PE 36.80x, ROE 18.67 percent. Merck India trades at Rs 10,208 Cr market cap, PE 31.22x, ROE 62.32 percent, Div 6.75 percent. Merck India has a remarkable ROE of 62.32 percent and a high dividend yield. Emcure is larger but at a higher PE with much lower ROE.

Emcure Pharmaceuticals vs Merck India: Quick Comparison Table

The Emcure Pharmaceuticals vs Merck India comparison table below summarises the key metrics covered in this article side by side.

Parameter	Emcure Pharmaceuticals	Merck India
Sector	Branded generics: women's health, oncology, ARV (India + export)	MNC branded healthcare: Neurobion, Becosules, Glucophage, Cetaphil
Market Cap	Rs 37,502 Cr	Rs 10,208 Cr
P/E Ratio	36.80x	31.22x
ROE	18.67%	62.32%
Debt to Equity	0.31	0.02
Dividend Yield	0.18%	6.75%
Parent	Doshi family (Indian promoter)	Merck KGaA (Germany)

Conclusion

The Emcure Pharmaceuticals vs Merck India comparison above covers the key data points on reach, products, results and valuation. Emcure Pharmaceuticals vs Merck India covers an Indian-origin branded generic pharma company versus an MNC healthcare subsidiary. Emcure has scale and a specialty branded generics franchise. Merck India has exceptional capital efficiency with ROE of 62.32 percent from its branded healthcare model and pays a 6.75 percent dividend yield. Emcure vs Merck India investors should review India prescription market share, new product launches, Emcure's women's health pipeline and Merck India's Cetaphil skincare distribution. Consult a SEBI-registered advisor for personalised guidance.

Download the Univest iOS App or Univest Android App to track Emcure Pharmaceuticals and Merck India live price and get daily stock recommendations.

Disclaimer: Data and figures in this article are sourced from publicly available information, including company results filings and exchange data, and are current as of the time of writing. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

Frequently Asked Questions

What does Emcure Pharmaceuticals sell?

Ans. Emcure sells branded generic medicines primarily in gynecology (fertility, hormones), oncology (cancer supportive care), HIV/ARV (antiretrovirals for AIDS treatment), cardiovascular and vitamins/minerals segments in India and internationally.

What does Merck India sell?

Ans. Merck India (subsidiary of Merck KGaA Germany) sells Neurobion (B vitamins for nerve health), Becosules (B vitamins), Glucophage (Metformin for diabetes), Polybion, Evion (Vitamin E) and Cetaphil (skincare) in India.

Why is Merck India ROE so high?

Ans. Merck India's ROE of 62.32 percent reflects its asset-light, low-capital branded healthcare model. The company primarily imports and sells branded products through Indian distribution channels without heavy manufacturing assets.

What is Cetaphil?

Ans. Cetaphil is a dermatologist-recommended skincare brand known for gentle face wash and moisturisers. In India, Cetaphil is distributed by Merck India and has become a major over-the-counter skincare brand.